Zurampic (lesinurad)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- lesinurad
- Company
- Grünenthal GmbH
- Status
- Withdrawn
- Therapeutic area
- Hyperuricemia
- EU approval
- Thu 18 Feb 2016
- Designations
- Additional monitoring
- Application
- EMEA/H/C/003932
- ATC
- M04AB05
- Official record
- www.ema.europa.eu
Indication
Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Duzallo Withdrawn · Grunenthal GmbH
Follow Zurampic
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.